10.1016/j.freeradbiomed.2018.03.036 Free Radical
In her presentation, Caroline Geisler, Assistant Professor at the University of Kentucky College of Pharmacy, explained: For example, one study of about 9,000 matched individuals on tirzepatide or semaglutide found that after six months, non-diabetic patients had, on average, a 2% greater weight loss than those with type 2 diabetes
Her research focused on brain aging, specifically how estrogens and reproductive aging influence the aging brain's synapses and mitochondria
Click [...] To view or add a comment, sign in $NVO has started a Phase 1 trial for its new obesity drug candidate LX9851, developed with Lexicon Pharmaceuticals The drug is oral and works differently from current GLP-1 treatments, targeting fat metabolism and satiety signals The study will assess safety in overweight and obese patients, with results expected in Q1 2027 Lexicon receives a $10M milestone payment and could earn up to $1B plus royalties if successful #stocks #Investing To view or add a comment, sign in 16,835 followers
In one study, 50 participants that were diagnosed with a thyroid disorder were split into two groups treatment and control
The developer did warn consumers about common side effects, like abdominal pain, nausea, vomiting, diarrhea, constipation, and potential risk of pancreatitis, gallbladder issues, dehydration-related kidney problems, thyroid issues, hypoglycemia, suicidal ideation, and allergic reactions